HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
Stocks · News reference
Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT
BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIaInitial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse
Dutch Bros, SoundHoundAI, Kohl's and Ondas are among the top ten most-heavily shorted stocks in the market right now.